The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease
Abstract
BACKGROUND: Reductions in cholinergic function occur in Alzheimer disease (AD) and dementia with Lewy bodies and correlate with cognitive decline. However, whether such alterations appear in early-stage disease is unclear. OBJECTIVE: To examine the timing of cholinergic deficits in AD and dementia with Lewy bodies. METHODS: Autopsy series of 89 patients with AD and 50 patients with the Lewy body variant of AD (LBV). Stage of disease was stratified according to results of the last Mini-Mental State Examination (MMSE) before death as mild, moderate, severe, or very severe. We analyzed choline acetyltransferase (ChAT) activity in the midfrontal, superior temporal, and inferior parietal cortices. RESULTS: Although compared with a normal control group ChAT activity was decreased in the AD and LBV cohorts, ChAT activity reduction for the LBV cohort was much greater. Moreover, although the decline in ChAT activity in the AD cohort compared with the normal control group was significant only for patients in later stages of the illness, the decline in the LBV cohort was significant for those who died with mild-stage disease. When less impaired patients in each cohort (MMSE, > or = 10) underwent separate analysis, the relationship of ChAT activity with the MMSE score was strong and significant for the LBV cohort alone. CONCLUSIONS: Although cholinergic deficits are seen in both AD and LBV, loss of ChAT activity is less severe and occurs later in the clinical course of AD. Conversely, in LBV, loss of ChAT activity is already prominent in the earliest stages of the illness, suggesting that cholinergic replacement therapy may be more effective in LBV than in AD, especially in mild-stage disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Self-citationAlzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · cited 2×
“In AD, in which memory impairment is prominent, cholinergic function has been found to be markedly decreased, mainly as a result of neuronal loss in the basal forebrain, especially in the nucleus basalis of Meynert.(1) The activity of choline acetyltransferase (ChAT), the presynaptic synthetic enzyme for acetylcholine…”
BackgroundSynapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
Hansen, L., Salmon, D., Galasko, D., Masliah, E., Katzman, R., DeTeresa, R., Thal, L., Pay, M. M., Hofstetter, R., Klauber, M., et al. (1990) · Neurology · doi:10.1212/wnl.40.1.1 · Cited by 1,068
Self-citationSome morphometric aspects of the brain in senile dementia of the alzheimer type
Terry, R. D., Peck, A., DeTeresa, R., Schechter, R., & Horoupian, D. S. (1981) · Annals of Neurology · doi:10.1002/ana.410100209 · Cited by 801
Wilcock, G. K., Esiri, M. M., Bowen, D. M., & Smith, C. C. T. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90045-4 · Cited by 553
Cited by
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
“Numerous CPC studies have assessed the association between NFTs and cognitive status (38, 98, 154, 158, 162, 185, 188, 189, 191, 223 Y 232, 235 Y 240, 244, 250 Y 252, 258, 261, 264, 287 Y 296).”
Self-citationConsciousness without a cerebral cortex: A challenge for neuroscience and medicine
Merker, B. (2007) · Behavioral and Brain Sciences · doi:10.1017/s0140525x07000891 · Cited by 868
Webster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755
“…seen in AD (Blessed et al., 1968; Tomlinson et al., 1970; Duyckaerts et al., 1990, 1998; Berg et al., 1998; Gold et al., 2000; Mungas et al., 2001; Tiraboschi et al., 2002, 2004; Guillozet et al., 2003; Kraybill et al., 2005; Holtzer et al., 2006; Markesbery et al., 2006; Nelson et al., 2007a,…”
The cholinergic system and Parkinson disease
Bohnen, N. I., & Albin, R. L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.048 · Cited by 566
Neuropsychological Assessment of Dementia
Salmon, D. P., & Bondi, M. W. (2009) · Annual Review of Psychology · doi:10.1146/annurev.psych.57.102904.190024 · Cited by 442
Collerton, D., Perry, E., & McKeith, I. (2005) · Behavioral and Brain Sciences · doi:10.1017/s0140525x05000130 · Cited by 437
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET
Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., Ota, T., Asahina, M., Fukushi, K., Kuwabara, S., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181ab2b58 · Cited by 366
Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease
Whitwell, J. L., Weigand, S. D., Shiung, M. M., Boeve, B. F., Ferman, T. J., Smith, G. E., Knopman, D. S., Petersen, R. C., Benarroch, E. E., Josephs, K. A., et al. (2007) · Brain · doi:10.1093/brain/awl388 · Cited by 349
Olfactory Dysfunction in Neurodegenerative Diseases
Marin, C., Vilas, D., Langdon, C., Alobid, I., López-Chacón, M., Haehner, A., Hummel, T., & Mullol, J. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0796-4 · Cited by 274
Choi, J. S., Nurul Islam, M., Yousof Ali, M., Kim, E. J., Kim, Y. M., & Jung, H. A. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.11.020 · Cited by 269
Cholinergic Dysfunction in Parkinson’s Disease
Müller, M. L. T. M., & Bohnen, N. I. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0377-9 · Cited by 264
1 H MR spectroscopy in common dementias
Kantarci, K., Petersen, R. C., Boeve, B. F., Knopman, D. S., Tang-Wai, D. F., O’Brien, P. C., Weigand, S. D., Edland, S. D., Smith, G. E., Ivnik, R. J., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000141849.21256.ac · Cited by 262
Seltzer, B. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.1011 · Cited by 256
Nelson, P. T., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Jicha, G. A., Smith, C. D., Davis, D. G., Poduska, J. W., Patel, E., Mendiondo, M. S., et al. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00244.x · Cited by 239
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance
Geula, C., Dunlop, S. R., Ayala, I., Kawles, A. S., Flanagan, M. E., Gefen, T., & Mesulam, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15471 · Cited by 102
Stylianou, M., Murphy, N., Peraza, L. R., Graziadio, S., Cromarty, R., Killen, A., O' Brien, J. T., Thomas, A. J., LeBeau, F. E. N., & Taylor, J.-P. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.03.013 · Cited by 79
Marcone, A., Garibotto, V., Moresco, R. M., Florea, I., Panzacchi, A., Carpinelli, A., Virta, J. R., Tettamanti, M., Borroni, B., Padovani, A., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111748 · Cited by 51
Shimada, H., Hirano, S., Sinotoh, H., Ota, T., Tanaka, N., Sato, K., Yamada, M., Fukushi, K., Irie, T., Zhang, M. R., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4338 · Cited by 40
“In a postmortem study, Tiraboschi et al. (2002) reported that loss of choline acetyltransferase (ChAT) activity is less severe and occurs later in the clinical course of AD while loss of ChAT activity is already prominent in the earliest stages of the illness in DLB.”
BackgroundLongitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration
Kantarci, K., Nedelska, Z., Chen, Q., Senjem, M. L., Schwarz, C. G., Gunter, J. L., Przybelski, S. A., Lesnick, T. G., Kremers, W. K., Fields, J. A., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac013 · Cited by 39
Dauwan, M., Linszen, M. M. J., Lemstra, A. W., Scheltens, P., Stam, C. J., & Sommer, I. E. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.013 · Cited by 37
Utility of quantitative EEG in early Lewy body disease
Massa, F., Meli, R., Grazzini, M., Famà, F., De Carli, F., Filippi, L., Arnaldi, D., Pardini, M., Morbelli, S., & Nobili, F. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.05.007 · Cited by 35
Roussotte, F. F., Gutman, B. A., Hibar, D. P., Madsen, S. K., Narr, K. L., Thompson, P. M., & (ADNI), A. D. N. I. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.011 · Cited by 19
Suzuki, Y., Suzuki, M., Shigenobu, K., Shinosaki, K., Aoki, Y., Kikuchi, H., Baba, T., Hashimoto, M., Araki, T., Johnsen, K., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0265484 · Cited by 10
“The cholinergic deficits are greater and occur earlier in DLB compared to AD [32, 33].”
Metadata
- Authors
- Tiraboschi, P., Hansen, L. A., Alford, M., Merdes, A., Masliah, E., Thal, L. J., & Corey-Bloom, J.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2002-10-01
- Volume
- 59
- Issue
- 10
- Pages
- 946
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2148206024
- Cited by
- 170
- References
- 9
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.